Valuation: Q/C Technologies, Inc.

Capitalization 28.54M 24.53M 22.98M 21.42M 39.57M 2.57B 43.04M 269M 104M 1.21B 107M 105M 4.44B P/E ratio 2023
-1.46x
P/E ratio 2024 -0.1x
Enterprise value 20.03M 17.22M 16.13M 15.04M 27.77M 1.8B 30.21M 189M 72.86M 852M 75.19M 73.59M 3.11B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
94.88%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.01%
1 week+91.34%
Current month+91.34%
1 month+121.68%
3 months+107.58%
6 months-57.08%
Current year-94.04%
More quotes
1 week 3.25
Extreme 3.25
8.17
1 month 2.5
Extreme 2.5
8.17
Current year 2.5
Extreme 2.5
152
1 year 2.5
Extreme 2.5
164
3 years 2.5
Extreme 2.5
8,938.51
5 years 2.5
Extreme 2.5
29,850.03
10 years 2.5
Extreme 2.5
29,850.03
More quotes
Manager TitleAgeSince
Director of Finance/CFO 51 2021-04-14
President 73 2024-06-13
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2025-08-31
Director/Board Member 64 2017-08-07
Director/Board Member 73 2024-04-07
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.01%+91.34%-94.39%-99.88% 28.54M
-1.58%-1.13%-15.86%+486.37% 72.73B
-6.83%+9.66%+418.86%+202.67% 13.08B
-3.75%-6.48%+215.97%+2,677.02% 12.67B
-4.07%+6.49% - - 7B
+0.18%+1.30%+1.00% - 5.31B
-0.76%-1.75%+40.41%+702.04% 2.89B
+4.44%+14.07%+125.98%+535.00% 1.94B
-3.46%+4.09% - - 1.35B
-4.59%-7.56%-58.51%-62.95% 620M
Average -1.95%+11.00%+79.18%+634.32% 11.76B
Weighted average by Cap. -1.16%+0.34%+67.63%+721.17%
See all sector performances

Financials

2023 2024
Net sales - -
Net income -4M -3.44M -3.22M -3M -5.55M -360M -6.03M -37.68M -14.55M -170M -15.01M -14.69M -622M -23.36M -20.08M -18.81M -17.53M -32.38M -2.1B -35.22M -220M -84.95M -993M -87.67M -85.8M -3.63B
Net Debt -4.87M -4.19M -3.93M -3.66M -6.76M -439M -7.35M -45.91M -17.73M -207M -18.29M -17.9M -758M -8.51M -7.31M -6.85M -6.39M -11.79M -766M -12.83M -80.13M -30.94M -362M -31.93M -31.25M -1.32B
More financial data * Estimated data
Logo Q/C Technologies, Inc.
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
Employees
2
More about the company
Date Price Change Volume
25-12-05 6.850 $ -1.01% 28,777,227
25-12-04 6.920 $ +48.18% 96,020,802
25-12-03 4.670 $ +38.17% 54,712,457
25-12-02 3.380 $ 0.00% 88,408
25-12-01 3.380 $ -5.59% 99,934

Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST

More quotes